



May 6, 2014

## Arrowhead to Present at Upcoming Scientific Conferences

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present at multiple scientific conferences in May.

Scheduled conference presentations include the following:

### **TIDES 2014** - Providence, RI, May 12-15

*May 12, 2014* - An oral presentation titled, "**Using Endosomal Escape Agents for siRNA Delivery in vivo**," will be presented at the workshop entitled "In vivo Delivery of Therapeutic Oligonucleotides: Challenges, Considerations and Solutions," by David Lewis, Ph.D., Chief Scientific Officer

*May 14, 2014* - An oral presentation titled, "**Next Generation Dynamic Polyconjugates for siRNA Delivery in vivo**," will be presented by Aaron Almeida, Ph.D., Senior Scientist II

### **10th International Symposium on Polymer Therapeutics** - Valencia, Spain, May 19-21

*May 19, 2014* - An oral presentation titled, "**Polymer-Based Vehicles for siRNA Delivery in vivo**," will be presented by David Rozema, Ph.D., Vice President, Chemistry

### **ASGCT 17<sup>th</sup> Annual Meeting** - Washington, DC, May 21-24

*May 21, 2014* - An oral presentation titled, "**Development of an siRNA-Based Therapeutic for Chronic HBV Infection Using DPC Technology**," will be presented by David Lewis, Ph.D., Chief Scientific Officer

## About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead's pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology.

For more information please visit <http://www.arrowheadresearch.com>, or follow us on Twitter [@ArrowRes](https://twitter.com/ArrowRes). To be added to the Company's email list to receive news directly, please send an email to [ir@arrowres.com](mailto:ir@arrowres.com).

Arrowhead Research Corporation  
Vince Anzalone, CFA  
626-304-3400  
[ir@arrowres.com](mailto:ir@arrowres.com)

or

#### **Investor Relations:**

The Trout Group  
Lauren Glaser  
646-378-2972  
[ir@arrowres.com](mailto:ir@arrowres.com)

or

#### **Media:**

Russo Partners  
Martina Schwarzkopf, Ph.D.  
212-845-4292

[martina.schwarzkopf@russopartnersllc.com](mailto:martina.schwarzkopf@russopartnersllc.com)

Source: Arrowhead Research Corporation

News Provided by Acquire Media